Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) is proud to announce the addition of Agilent Technologies’ RapidFire Mass Spectrometry analysis capabilities to their High Throughput Screening facilities in Hamburg.

RapidFire, a robust, in-line solid phase extraction technology enables ultrafast, direct analysis of native compounds for a wide variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic areas. Evotec is the first Pharmaceutical Contract Research Organisation in Europe to offer these services. The Evotec facility in Hamburg will be equipped with state-of-the-art technology from Agilent including multiple RapidFire High-throughput Mass Spectrometry Systems and 6460 Triple Quadrupole instrumentation.

“Evotec is the ideal partner for Agilent Technologies as we expand this industry-leading platform into the European Contract Research market,” said Gustavo Salem, Agilent Vice President and General Manager, Biological Systems Division. “Evotec’s leadership role as a drug discovery service provider will ensure that this market is exposed to the capabilities of Agilent’s RapidFire and gold-standard Mass Spectrometry platforms.”

Mario Polywka, Chief Operating Officer for Evotec commented: “The addition of Agilent’s RapidFire Mass Spectrometry analysis

instrumentation and capabilities is a tremendous boost to Evotec’s best in class screening platform. Working with Agilent will ensure that these systems are brought into operation quickly and that our partners and collaborators will benefit from further efficiencies in lead discovery.”

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating stateof-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, Novartis and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in the field of Alzheimer’s disease. For additional information please go to www.evotec.com.

ABOUT AGILENT

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company’s 18,700 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.